Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
Annals of Oncology（2019）
Key words
EGFR,osimertinib,PD-1,irAE,TKI
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined